{"doi":"10.1002/smll.202405178","title":"Nanomedicine for Women's Health","abstract":"The field of medicine known as “Women's Health” focuses on diagnosing and treating diseases and disorders affecting a woman's physical and mental well-being. Women face unique health issues and conditions, including but not limited to pregnancy complications, menopause, gynecological disorders, and malignancies. The Eunice Kennedy Shriver National Institute of Child Health and Human Development also indicated that while both men and women share certain health issues, they are affected differently. For instance, breast cancer, osteoarthritis, and urine incontinence are more prevalent in women. In addition, women are more likely to die after a heart attack. Consequently, therapeutic and diagnostic strategies must be meticulously designed for women's health issues. The available literature indicates that nanotechnology is a promising strategy for developing of effective and personalized treatment modalities for various diseases, and it has the potential to revolutionize women's health in several key areas. For instance, it enables the development of targeted drug delivery systems that can enhance the efficacy of treatments while minimizing side effects. This is particularly crucial in treating diseases such as gynecological cancers and endometriosis, where precision in targeting disease cells can significantly improve patient outcomes. Furthermore, nanomedicine holds promise in the realm of female reproductive health. Nanoparticles can be used to deliver various therapeutic agents to specific sites within the reproductive system, offering new treatment options for conditions such as infertility, polycystic ovary syndrome, and others. Furthermore, nanotechnology-enabled imaging techniques can provide more precise and earlier detection of gynecological diseases, allowing for timely intervention and better management of these conditions. Finally, nanomedicine has significant potential in addressing pregnancy complications and enhancing maternal and fetal health. For instance, nanoparticles can be designed to accumulate in the implantation site, enabling targeted delivery of drugs or imaging agents to the placenta or fetus. This could be crucial for diagnosing and treating conditions like ectopic pregnancy, preeclampsia, or fetal growth restriction. This special issue on “Nanomedicine for Women's Health” presents a comprehensive collection of twenty papers (1 Perspective, 4 Research articles, and 15 Reviews) highlighting the transformative potential of nanotechnology in women's healthcare. The papers collectively cover a broad spectrum of innovative therapeutic and diagnostic approaches, showcasing the versatility and efficacy of nanomedicine across various health conditions and diseases that primarily affect women. A substantial number of published articles have reported on the application of innovative nanomedicine platforms for treating and imaging gynecological and breast cancers. For instance, Garbuzenko et al. introduced an advanced nanotechnology-based strategy for the personalized treatment of ovarian carcinoma, meticulously tailored to the individual genetic profile of the patient's tumor.[1] By employing targeted nanoparticle-based delivery systems loaded with the most effective siRNA and anticancer agents selected for each individual patient, they demonstrated that these personalized treatment protocols significantly suppress drug resistance, inhibit tumor progression, and prevent the development of metastases while mitigating the adverse side effects typically associated with conventional therapies. In another study, Naguib et al. developed an innovative therapeutic approach for type II endometrial cancer utilizing polymeric nanoparticles loaded with CIP2b, a novel derivative of the fluoroquinolone antibiotic ciprofloxacin.[2] Animal studies demonstrated that CIP2b-loaded nanoparticles, when administered in combination with paclitaxel, significantly reduced tumor growth without causing any apparent off-target toxicity. Th","journal":"Small","year":2024,"id":468626,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9625,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":304336,"name":"Oleh Taratula","orcid":"0000-0002-6227-9110","position":1,"is_corresponding":false},{"id":235166,"name":"Tamara Minko","orcid":"0000-0002-1633-4705","position":0,"is_corresponding":true}],"reference_count":20,"raw_metadata":null,"created_at":"2026-07-19T02:05:23.500722Z","pmid":"39032120","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}